ClinicalTrials.gg
CompletedNCT02311894Updated Jan 8, 2019Results posted

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

A Phase 4 interventional study of Somatropin in Growth Hormone Deficiency, sponsored by Genentech, Inc.. Completed at 33 sites in United States. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
3 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
27th of 60
82 · median 66
Started
2015
with 2 others
Phase 4
19 of 60
none open now
Registered
47th of 60
by date

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 27th largest by enrollment, is one of 3 that started in 2015, is one of 19 in phase 4, and was the 47th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naïve to prior recombinant human growth hormone (rhGH) treatment. The study is designed to characterize the immunogenicity profile of somatropin (rDNA origin) injection when administered daily subcutaneously for 12 months. The clinical impact of immunogenicity will also be assessed.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bone age less than equal to (\</=) 9 years (females) or \</= 11 years (males) as determined by X-ray of the left hand and wrist using Greulich and Pyle method and obtained within the 12 months prior to enrollment
  • Prepubertal (Tanner I) males and females by physical examination
  • Diagnosis of GHD (stimulated GH less than [\<] 10 nanograms per milliliter [ng/mL]) by two standard pharmacologic tests obtained up to 12 months prior to /assent
  • Normal thyroid function test within the 12 months prior to informed consent/assent
  • Normal complete blood counts within 12 months prior to informed consent/assent
  • Documentation of prior height and weight measurements, with height standard deviation score (SDS) \</= 5th percentile for idiopathic isolated GHD participants

Exclusion criteria

Exclusion Criteria:

  • Any previous rhGH treatment
  • Short stature etiologies other than GHD
  • Acute critical illness or uncontrolled chronic illness, which in the opinion of the investigator and medical monitor, would interfere with participation in this study, interpretation of the data, or pose a risk to participant safety
  • Chronic illnesses such as inflammatory bowel disease, celiac disease, heart disease, and diabetes
  • Bone diseases such as achondroplasia or hypochondroplasia, intracranial tumor, irradiation, and traumatic brain injury
  • Participants receiving oral or inhaled chronic therapy (greater than [>] 3 months) for other medical conditions other than central adrenal insufficiency
  • Participants who require higher (2 times or greater than maintenance) doses of corticosteroids for more than 5 days in the 6 months prior to enrollment in the study
  • Participants with active or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated
  • Females with Turner syndrome regardless of their GH status
  • Prader-Willi syndrome regardless of GH status
  • Born small for gestational age regardless of GH status
  • Presence of scoliosis requiring monitoring
  • Previous participation in another clinical trial or investigation of GH, treatment for growth failure, or treatment with a biologic agent
  • Participants with closed epiphyses
  • Participants with a known to somatropin, , or diluent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Somatropin

    Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.

    Drug: Somatropin

Interventions

  • Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.

    Also known as: Nutropin AQ v1.1

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1

    Participants who were tested positive to anti-GH antibody after initiation of study treatment.

    Time frame: Baseline up to 1 year

Secondary outcomes

  1. Percentage of Participants Who Exhibit Functional Growth Attenuation

    Growth attenuation is defined as initial growth response greater than pretreatment velocity followed by reduction in growth response to below the pretreatment velocity in the subsequent 6- to 12-month treatment period or reaching ≤ 2 cm per year.

    Time frame: Baseline up to 1 year

  2. Percentage of Participants With Neutralizing Antibodies

    Among participants who developed positive anti-GH antibody post-baseline, participants who were tested positive to neutralizing anti-GH antibody during study participation.

    Time frame: Baseline up to 1 year

  3. Annualized Growth Velocity at Months 6 and 12 (Change From Baseline)

    Annualized growth velocity is defined as (height - baseline height) / (date of height assessment - date of baseline)\*365.25. Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits).

    Time frame: Months 6, 12

  4. Height Standard Deviation Score (SDS) at Months 6 and 12 (Change From Baseline)

    Height Standard Deviation Score (SDS) allows for the comparison of a participants height to that of others in the same age group. Therefore, the average height for that age group will have the SDS of 0. In this study, the starting Height SDS score was ≤ -1.5 (≤ 5th percentile). Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits.

    Time frame: Months 6, 12

  5. Percentage of Participants With Adverse Events

    Among participants who received at least one dose of study drug, those who reported at least one adverse event during study participation.

    Time frame: Baseline up to 1 year

07

Results

Posted Nov 15, 2018

Participant flow

Participant flow — Overall Study
MilestoneSomatropin
Started82
Modified itt population81
Completed78
Not completed4
Withdrew: Discontinued in error1
Withdrew: Lost to follow-up1
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1

Participants who were tested positive to anti-GH antibody after initiation of study treatment.

Time frame:
Baseline up to 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1
percentage of participantsSomatropin
Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.13.7 (0.77 to 10.44)
SecondaryPercentage of Participants Who Exhibit Functional Growth Attenuation

Growth attenuation is defined as initial growth response greater than pretreatment velocity followed by reduction in growth response to below the pretreatment velocity in the subsequent 6- to 12-month treatment period or reaching ≤ 2 cm per year.

Time frame:
Baseline up to 1 year
Reported as:
Number · percentage of participants
Percentage of Participants Who Exhibit Functional Growth Attenuation
percentage of participantsSomatropin
Percentage of Participants Who Exhibit Functional Growth Attenuation2.6 (0.31 to 8.96)
SecondaryPercentage of Participants With Neutralizing Antibodies

Among participants who developed positive anti-GH antibody post-baseline, participants who were tested positive to neutralizing anti-GH antibody during study participation.

Time frame:
Baseline up to 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibodies
percentage of participantsSomatropin
Percentage of Participants With Neutralizing Antibodies0
SecondaryAnnualized Growth Velocity at Months 6 and 12 (Change From Baseline)

Annualized growth velocity is defined as (height - baseline height) / (date of height assessment - date of baseline)\*365.25. Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits).

Time frame:
Months 6, 12
Reported as:
Mean · cm/year
Annualized Growth Velocity at Months 6 and 12 (Change From Baseline)
cm/yearSomatropin
6 months (Anti-GH Antibody Positive)5.3 ± 2.89
6 months (Anti-GH Antibody Negative)5.5 ± 2.64
12 months (Anti-GH Antibody Positive)5.2 ± 3.61
12 months (Anti-GH Antibody Negative)4.9 ± 2.40
SecondaryHeight Standard Deviation Score (SDS) at Months 6 and 12 (Change From Baseline)

Height Standard Deviation Score (SDS) allows for the comparison of a participants height to that of others in the same age group. Therefore, the average height for that age group will have the SDS of 0. In this study, the starting Height SDS score was ≤ -1.5 (≤ 5th percentile). Results are presented according to anti-GH antibody status (positive included all participants that were anti-GH antibody positive at least once post-baseline visit and anti-GH antibody negative population included all participants that were anti-GH antibody negative at all post-baseline visits.

Time frame:
Months 6, 12
Reported as:
Mean · SDS
Height Standard Deviation Score (SDS) at Months 6 and 12 (Change From Baseline)
SDSSomatropin
6 months (Anti-GH Antibody Positive)0.3 ± 0.11
6 months (Anti-GH Antibody Negative)0.4 ± 0.17
12 months (Anti-GH Antibody Positive)0.8 ± 0.15
12 months (Anti-GH Antibody Negative)0.7 ± 0.25
SecondaryPercentage of Participants With Adverse Events

Among participants who received at least one dose of study drug, those who reported at least one adverse event during study participation.

Time frame:
Baseline up to 1 year
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsSomatropin
Percentage of Participants With Adverse Events69.5

Adverse events

Collected over Adverse events (AEs) were reported from Day 1 until 28 days after last dose of study medication for up to 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin0/82 (0%)0/82 (0%)40/82 (48.8%)
Most frequent other events
Most frequent other events
EventSomatropin
HeadacheNervous system disorders17/82
VomitingGastrointestinal disorders12/82
Upper respiratory tract infectionInfections and infestations8/82
Injection site bruisingGeneral disorders7/82
Pharyngitis streptococcalInfections and infestations6/82
RashSkin and subcutaneous tissue disorders6/82
PyrexiaGeneral disorders5/82
NasopharyngitisInfections and infestations5/82

Baseline characteristics

Age, Continuous
Age, Continuous(years)Somatropin
Mean9.0 ± 1.91
Sex: Female, Male
Sex: Female, Male(Participants)Somatropin
Female17
Male65
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Somatropin
Hispanic or Latino11
Not Hispanic or Latino70
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Somatropin
Asian5
Black or African American2
Multiple1
Other3
Unknown3
White68
08

Study locations

33 sites
  • Arkansas Children's Hospital Research Institute
    Little Rock, Arkansas 72202, United States
  • Children'S Hospital of Orange County
    Orange, California 92868-3874, United States
  • Center of Excellence in Diabetes & Endocrinology
    Sacramento, California 95821, United States
  • San Diego Medical Group; Pediatric Endocrinology
    San Diego, California 92123, United States
  • Rocky Mountain Pediatric Endocrinology, PC
    Centennial, Colorado 80112, United States
  • Pediatric Endocrine Associates
    Greenwood Village, Colorado 80111, United States
  • Nemours Children's Clinic - of the Nemours Foundation
    Jacksonville, Florida 32207, United States
  • Miami Children's Hospital
    Miami, Florida 33155-3009, United States
  • Nemours Childrens Clinic
    Orlando, Florida 32801, United States
  • The Pediatric Endocrine Office of Larry C. Deeb
    Tallahassee, Florida 32308, United States
  • Pediatric Endrocine Assoc
    Tampa, Florida 33607, United States
  • USF Diabetes Center
    Tampa, Florida 33612, United States
  • Emory Children's Center
    Atlanta, Georgia 20010, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Barry J Reiner, MD, LLC
    Baltimore, Maryland 21229, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Baystate Endocrinology and Diabetes; Baystate Children's Specialty Center, Pediatric Endocrinology
    Springfield, Massachusetts 01199, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-0934, United States
  • University of Minnesota Childrens' Hospital
    Minneapolis, Minnesota 55455, United States
  • Children's Healthcare d.b.a Children's Hospitals and Clinics of Minnesota
    Saint Paul, Minnesota 55102, United States
  • Children's Mercy Hospitals & Clinics; Pulmonology
    Kansas City, Missouri 64108, United States
  • Hackensack University Medical Center PARTNER
    Hackensack, New Jersey 07601, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • UNC General Pediatrics Clinic
    Chapel Hill, North Carolina 27514, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Milton S Hershey Ped Sub Spclt
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina; MUSC Pediatric Endocrinology
    Charleston, South Carolina 29425, United States
  • Endocrine Associates of Dallas
    Dallas, Texas 75231, United States
  • Cook Children's Hospital
    Fort Worth, Texas 76104, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Nov 2017, 31 months.

Results were first posted in Nov 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2014
First posted
Dec 9, 2014
StartActual
Mar 31, 2015
Primary completionActual
Nov 8, 2017
CompletionActual
Nov 8, 2017
Results first posted
Nov 15, 2018
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02311894
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2014
Start date
Mar 31, 2015
Primary completion
Nov 8, 2017
Completion
Nov 8, 2017
Results posted
Nov 15, 2018
Last update
Jan 8, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion